nodes	percent_of_prediction	percent_of_DWPC	metapath
Tobramycin—Swelling—Simvastatin—atherosclerosis	0.0049	0.0049	CcSEcCtD
Tobramycin—Muscular weakness—Rosuvastatin—atherosclerosis	0.00481	0.00481	CcSEcCtD
Tobramycin—Bronchitis—Rosuvastatin—atherosclerosis	0.00454	0.00454	CcSEcCtD
Tobramycin—Blood alkaline phosphatase increased—Pravastatin—atherosclerosis	0.0045	0.0045	CcSEcCtD
Tobramycin—Deafness—Pravastatin—atherosclerosis	0.00437	0.00437	CcSEcCtD
Tobramycin—Renal failure acute—Pravastatin—atherosclerosis	0.00424	0.00424	CcSEcCtD
Tobramycin—Neuropathy peripheral—Rosuvastatin—atherosclerosis	0.00412	0.00412	CcSEcCtD
Tobramycin—Aspartate aminotransferase increased—Ezetimibe—atherosclerosis	0.00408	0.00408	CcSEcCtD
Tobramycin—Muscular weakness—Ezetimibe—atherosclerosis	0.004	0.004	CcSEcCtD
Tobramycin—Eosinophilia—Lovastatin—atherosclerosis	0.00396	0.00396	CcSEcCtD
Tobramycin—Sinusitis—Rosuvastatin—atherosclerosis	0.00394	0.00394	CcSEcCtD
Tobramycin—Eosinophilia—Ezetimibe—atherosclerosis	0.00388	0.00388	CcSEcCtD
Tobramycin—Muscular weakness—Simvastatin—atherosclerosis	0.00381	0.00381	CcSEcCtD
Tobramycin—Rhinitis—Rosuvastatin—atherosclerosis	0.00378	0.00378	CcSEcCtD
Tobramycin—Pharyngitis—Rosuvastatin—atherosclerosis	0.00375	0.00375	CcSEcCtD
Tobramycin—Eosinophilia—Simvastatin—atherosclerosis	0.0037	0.0037	CcSEcCtD
Tobramycin—Upper respiratory tract infection—Ezetimibe—atherosclerosis	0.00364	0.00364	CcSEcCtD
Tobramycin—Dry skin—Niacin—atherosclerosis	0.00364	0.00364	CcSEcCtD
Tobramycin—Bronchitis—Simvastatin—atherosclerosis	0.0036	0.0036	CcSEcCtD
Tobramycin—Dry skin—Pravastatin—atherosclerosis	0.00358	0.00358	CcSEcCtD
Tobramycin—Muscular weakness—Niacin—atherosclerosis	0.0035	0.0035	CcSEcCtD
Tobramycin—Infestation NOS—Ezetimibe—atherosclerosis	0.0035	0.0035	CcSEcCtD
Tobramycin—Infestation—Ezetimibe—atherosclerosis	0.0035	0.0035	CcSEcCtD
Tobramycin—Neuropathy peripheral—Lovastatin—atherosclerosis	0.00349	0.00349	CcSEcCtD
Tobramycin—Upper respiratory tract infection—Simvastatin—atherosclerosis	0.00347	0.00347	CcSEcCtD
Tobramycin—Muscular weakness—Pravastatin—atherosclerosis	0.00345	0.00345	CcSEcCtD
Tobramycin—Neuropathy peripheral—Ezetimibe—atherosclerosis	0.00343	0.00343	CcSEcCtD
Tobramycin—Eosinophilia—Pravastatin—atherosclerosis	0.00335	0.00335	CcSEcCtD
Tobramycin—Sinusitis—Lovastatin—atherosclerosis	0.00334	0.00334	CcSEcCtD
Tobramycin—Bronchitis—Niacin—atherosclerosis	0.0033	0.0033	CcSEcCtD
Tobramycin—Sinusitis—Ezetimibe—atherosclerosis	0.00328	0.00328	CcSEcCtD
Tobramycin—Neuropathy peripheral—Simvastatin—atherosclerosis	0.00327	0.00327	CcSEcCtD
Tobramycin—Upper respiratory tract infection—Pravastatin—atherosclerosis	0.00314	0.00314	CcSEcCtD
Tobramycin—Sinusitis—Simvastatin—atherosclerosis	0.00313	0.00313	CcSEcCtD
Tobramycin—Pharyngitis—Ezetimibe—atherosclerosis	0.00311	0.00311	CcSEcCtD
Tobramycin—Connective tissue disorder—Ezetimibe—atherosclerosis	0.00308	0.00308	CcSEcCtD
Tobramycin—Weight decreased—Pravastatin—atherosclerosis	0.00306	0.00306	CcSEcCtD
Tobramycin—Angioedema—Rosuvastatin—atherosclerosis	0.003	0.003	CcSEcCtD
Tobramycin—Stomatitis—Niacin—atherosclerosis	0.00298	0.00298	CcSEcCtD
Tobramycin—Neuropathy peripheral—Pravastatin—atherosclerosis	0.00295	0.00295	CcSEcCtD
Tobramycin—Cough—Rosuvastatin—atherosclerosis	0.00287	0.00287	CcSEcCtD
Tobramycin—Angiopathy—Ezetimibe—atherosclerosis	0.00285	0.00285	CcSEcCtD
Tobramycin—Immune system disorder—Ezetimibe—atherosclerosis	0.00283	0.00283	CcSEcCtD
Tobramycin—Mediastinal disorder—Ezetimibe—atherosclerosis	0.00283	0.00283	CcSEcCtD
Tobramycin—Sinusitis—Pravastatin—atherosclerosis	0.00283	0.00283	CcSEcCtD
Tobramycin—Myalgia—Rosuvastatin—atherosclerosis	0.0028	0.0028	CcSEcCtD
Tobramycin—Rhinitis—Niacin—atherosclerosis	0.00275	0.00275	CcSEcCtD
Tobramycin—Erythema—Ezetimibe—atherosclerosis	0.00273	0.00273	CcSEcCtD
Tobramycin—Dysgeusia—Lovastatin—atherosclerosis	0.00273	0.00273	CcSEcCtD
Tobramycin—Rhinitis—Pravastatin—atherosclerosis	0.00271	0.00271	CcSEcCtD
Tobramycin—Confusional state—Rosuvastatin—atherosclerosis	0.0027	0.0027	CcSEcCtD
Tobramycin—Back pain—Lovastatin—atherosclerosis	0.00269	0.00269	CcSEcCtD
Tobramycin—Pharyngitis—Pravastatin—atherosclerosis	0.00268	0.00268	CcSEcCtD
Tobramycin—Visual impairment—Niacin—atherosclerosis	0.00265	0.00265	CcSEcCtD
Tobramycin—Back pain—Ezetimibe—atherosclerosis	0.00264	0.00264	CcSEcCtD
Tobramycin—Nervous system disorder—Rosuvastatin—atherosclerosis	0.00263	0.00263	CcSEcCtD
Tobramycin—Thrombocytopenia—Rosuvastatin—atherosclerosis	0.00263	0.00263	CcSEcCtD
Tobramycin—Vision blurred—Lovastatin—atherosclerosis	0.00262	0.00262	CcSEcCtD
Tobramycin—Visual impairment—Pravastatin—atherosclerosis	0.00261	0.00261	CcSEcCtD
Tobramycin—Erythema—Simvastatin—atherosclerosis	0.0026	0.0026	CcSEcCtD
Tobramycin—Ill-defined disorder—Lovastatin—atherosclerosis	0.00258	0.00258	CcSEcCtD
Tobramycin—Eye disorder—Niacin—atherosclerosis	0.00257	0.00257	CcSEcCtD
Tobramycin—Tinnitus—Niacin—atherosclerosis	0.00256	0.00256	CcSEcCtD
Tobramycin—Dysgeusia—Simvastatin—atherosclerosis	0.00255	0.00255	CcSEcCtD
Tobramycin—Angioedema—Lovastatin—atherosclerosis	0.00254	0.00254	CcSEcCtD
Tobramycin—Ill-defined disorder—Ezetimibe—atherosclerosis	0.00253	0.00253	CcSEcCtD
Tobramycin—Anaemia—Ezetimibe—atherosclerosis	0.00252	0.00252	CcSEcCtD
Tobramycin—Tinnitus—Pravastatin—atherosclerosis	0.00252	0.00252	CcSEcCtD
Tobramycin—Malaise—Lovastatin—atherosclerosis	0.00251	0.00251	CcSEcCtD
Tobramycin—Vertigo—Lovastatin—atherosclerosis	0.0025	0.0025	CcSEcCtD
Tobramycin—Angioedema—Ezetimibe—atherosclerosis	0.0025	0.0025	CcSEcCtD
Tobramycin—Angiopathy—Niacin—atherosclerosis	0.00249	0.00249	CcSEcCtD
Tobramycin—Leukopenia—Lovastatin—atherosclerosis	0.00249	0.00249	CcSEcCtD
Tobramycin—Malaise—Ezetimibe—atherosclerosis	0.00246	0.00246	CcSEcCtD
Tobramycin—Vision blurred—Simvastatin—atherosclerosis	0.00245	0.00245	CcSEcCtD
Tobramycin—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.00244	0.00244	CcSEcCtD
Tobramycin—Ill-defined disorder—Simvastatin—atherosclerosis	0.00242	0.00242	CcSEcCtD
Tobramycin—Paraesthesia—Rosuvastatin—atherosclerosis	0.00241	0.00241	CcSEcCtD
Tobramycin—Anaemia—Simvastatin—atherosclerosis	0.00241	0.00241	CcSEcCtD
Tobramycin—Erythema—Niacin—atherosclerosis	0.00239	0.00239	CcSEcCtD
Tobramycin—Cough—Ezetimibe—atherosclerosis	0.00238	0.00238	CcSEcCtD
Tobramycin—Angioedema—Simvastatin—atherosclerosis	0.00238	0.00238	CcSEcCtD
Tobramycin—Chest pain—Lovastatin—atherosclerosis	0.00237	0.00237	CcSEcCtD
Tobramycin—Myalgia—Lovastatin—atherosclerosis	0.00237	0.00237	CcSEcCtD
Tobramycin—Malaise—Simvastatin—atherosclerosis	0.00235	0.00235	CcSEcCtD
Tobramycin—Discomfort—Lovastatin—atherosclerosis	0.00234	0.00234	CcSEcCtD
Tobramycin—Vertigo—Simvastatin—atherosclerosis	0.00234	0.00234	CcSEcCtD
Tobramycin—Leukopenia—Simvastatin—atherosclerosis	0.00233	0.00233	CcSEcCtD
Tobramycin—Myalgia—Ezetimibe—atherosclerosis	0.00233	0.00233	CcSEcCtD
Tobramycin—Chest pain—Ezetimibe—atherosclerosis	0.00233	0.00233	CcSEcCtD
Tobramycin—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.00231	0.00231	CcSEcCtD
Tobramycin—Dysgeusia—Pravastatin—atherosclerosis	0.00231	0.00231	CcSEcCtD
Tobramycin—Discomfort—Ezetimibe—atherosclerosis	0.0023	0.0023	CcSEcCtD
Tobramycin—Pain—Rosuvastatin—atherosclerosis	0.00229	0.00229	CcSEcCtD
Tobramycin—Confusional state—Lovastatin—atherosclerosis	0.00229	0.00229	CcSEcCtD
Tobramycin—Anaphylactic shock—Lovastatin—atherosclerosis	0.00227	0.00227	CcSEcCtD
Tobramycin—Vision blurred—Niacin—atherosclerosis	0.00225	0.00225	CcSEcCtD
Tobramycin—Confusional state—Ezetimibe—atherosclerosis	0.00225	0.00225	CcSEcCtD
Tobramycin—Anaphylactic shock—Ezetimibe—atherosclerosis	0.00223	0.00223	CcSEcCtD
Tobramycin—Thrombocytopenia—Lovastatin—atherosclerosis	0.00223	0.00223	CcSEcCtD
Tobramycin—Vision blurred—Pravastatin—atherosclerosis	0.00222	0.00222	CcSEcCtD
Tobramycin—Chest pain—Simvastatin—atherosclerosis	0.00222	0.00222	CcSEcCtD
Tobramycin—Myalgia—Simvastatin—atherosclerosis	0.00222	0.00222	CcSEcCtD
Tobramycin—Feeling abnormal—Rosuvastatin—atherosclerosis	0.00221	0.00221	CcSEcCtD
Tobramycin—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.00219	0.00219	CcSEcCtD
Tobramycin—Discomfort—Simvastatin—atherosclerosis	0.00219	0.00219	CcSEcCtD
Tobramycin—Nervous system disorder—Ezetimibe—atherosclerosis	0.00219	0.00219	CcSEcCtD
Tobramycin—Angioedema—Niacin—atherosclerosis	0.00219	0.00219	CcSEcCtD
Tobramycin—Ill-defined disorder—Pravastatin—atherosclerosis	0.00218	0.00218	CcSEcCtD
Tobramycin—Thrombocytopenia—Ezetimibe—atherosclerosis	0.00218	0.00218	CcSEcCtD
Tobramycin—Anaemia—Pravastatin—atherosclerosis	0.00218	0.00218	CcSEcCtD
Tobramycin—Anorexia—Lovastatin—atherosclerosis	0.00217	0.00217	CcSEcCtD
Tobramycin—Skin disorder—Ezetimibe—atherosclerosis	0.00217	0.00217	CcSEcCtD
Tobramycin—Angioedema—Pravastatin—atherosclerosis	0.00215	0.00215	CcSEcCtD
Tobramycin—Vertigo—Niacin—atherosclerosis	0.00215	0.00215	CcSEcCtD
Tobramycin—Confusional state—Simvastatin—atherosclerosis	0.00214	0.00214	CcSEcCtD
Tobramycin—Leukopenia—Niacin—atherosclerosis	0.00214	0.00214	CcSEcCtD
Tobramycin—Urticaria—Rosuvastatin—atherosclerosis	0.00213	0.00213	CcSEcCtD
Tobramycin—Anaphylactic shock—Simvastatin—atherosclerosis	0.00213	0.00213	CcSEcCtD
Tobramycin—Malaise—Pravastatin—atherosclerosis	0.00212	0.00212	CcSEcCtD
Tobramycin—Abdominal pain—Rosuvastatin—atherosclerosis	0.00212	0.00212	CcSEcCtD
Tobramycin—Vertigo—Pravastatin—atherosclerosis	0.00212	0.00212	CcSEcCtD
Tobramycin—Leukopenia—Pravastatin—atherosclerosis	0.00211	0.00211	CcSEcCtD
Tobramycin—Cough—Niacin—atherosclerosis	0.00209	0.00209	CcSEcCtD
Tobramycin—Thrombocytopenia—Simvastatin—atherosclerosis	0.00208	0.00208	CcSEcCtD
Tobramycin—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.00207	0.00207	CcSEcCtD
Tobramycin—Cough—Pravastatin—atherosclerosis	0.00205	0.00205	CcSEcCtD
Tobramycin—Paraesthesia—Lovastatin—atherosclerosis	0.00204	0.00204	CcSEcCtD
Tobramycin—Myalgia—Niacin—atherosclerosis	0.00204	0.00204	CcSEcCtD
Tobramycin—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.00203	0.00203	CcSEcCtD
Tobramycin—Anorexia—Simvastatin—atherosclerosis	0.00203	0.00203	CcSEcCtD
Tobramycin—Dyspnoea—Lovastatin—atherosclerosis	0.00203	0.00203	CcSEcCtD
Tobramycin—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.00202	0.00202	CcSEcCtD
Tobramycin—Myalgia—Pravastatin—atherosclerosis	0.002	0.002	CcSEcCtD
Tobramycin—Chest pain—Pravastatin—atherosclerosis	0.002	0.002	CcSEcCtD
Tobramycin—Paraesthesia—Ezetimibe—atherosclerosis	0.002	0.002	CcSEcCtD
Tobramycin—Dyspnoea—Ezetimibe—atherosclerosis	0.00199	0.00199	CcSEcCtD
Tobramycin—Discomfort—Pravastatin—atherosclerosis	0.00198	0.00198	CcSEcCtD
Tobramycin—Hypersensitivity—Rosuvastatin—atherosclerosis	0.00198	0.00198	CcSEcCtD
Tobramycin—Decreased appetite—Lovastatin—atherosclerosis	0.00198	0.00198	CcSEcCtD
Tobramycin—Anaphylactic shock—Niacin—atherosclerosis	0.00195	0.00195	CcSEcCtD
Tobramycin—Pain—Lovastatin—atherosclerosis	0.00194	0.00194	CcSEcCtD
Tobramycin—Confusional state—Pravastatin—atherosclerosis	0.00194	0.00194	CcSEcCtD
Tobramycin—Decreased appetite—Ezetimibe—atherosclerosis	0.00194	0.00194	CcSEcCtD
Tobramycin—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.00194	0.00194	CcSEcCtD
Tobramycin—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.00192	0.00192	CcSEcCtD
Tobramycin—Asthenia—Rosuvastatin—atherosclerosis	0.00192	0.00192	CcSEcCtD
Tobramycin—Anaphylactic shock—Pravastatin—atherosclerosis	0.00192	0.00192	CcSEcCtD
Tobramycin—Paraesthesia—Simvastatin—atherosclerosis	0.00191	0.00191	CcSEcCtD
Tobramycin—Pain—Ezetimibe—atherosclerosis	0.00191	0.00191	CcSEcCtD
Tobramycin—Pruritus—Rosuvastatin—atherosclerosis	0.0019	0.0019	CcSEcCtD
Tobramycin—Skin disorder—Niacin—atherosclerosis	0.0019	0.0019	CcSEcCtD
Tobramycin—Dyspnoea—Simvastatin—atherosclerosis	0.0019	0.0019	CcSEcCtD
Tobramycin—Thrombocytopenia—Pravastatin—atherosclerosis	0.00188	0.00188	CcSEcCtD
Tobramycin—Feeling abnormal—Lovastatin—atherosclerosis	0.00187	0.00187	CcSEcCtD
Tobramycin—Anorexia—Niacin—atherosclerosis	0.00186	0.00186	CcSEcCtD
Tobramycin—Gastrointestinal pain—Lovastatin—atherosclerosis	0.00186	0.00186	CcSEcCtD
Tobramycin—Decreased appetite—Simvastatin—atherosclerosis	0.00185	0.00185	CcSEcCtD
Tobramycin—Feeling abnormal—Ezetimibe—atherosclerosis	0.00184	0.00184	CcSEcCtD
Tobramycin—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.00184	0.00184	CcSEcCtD
Tobramycin—Diarrhoea—Rosuvastatin—atherosclerosis	0.00183	0.00183	CcSEcCtD
Tobramycin—Anorexia—Pravastatin—atherosclerosis	0.00183	0.00183	CcSEcCtD
Tobramycin—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.00182	0.00182	CcSEcCtD
Tobramycin—Pain—Simvastatin—atherosclerosis	0.00182	0.00182	CcSEcCtD
Tobramycin—Urticaria—Lovastatin—atherosclerosis	0.00181	0.00181	CcSEcCtD
Tobramycin—Abdominal pain—Lovastatin—atherosclerosis	0.0018	0.0018	CcSEcCtD
Tobramycin—Body temperature increased—Lovastatin—atherosclerosis	0.0018	0.0018	CcSEcCtD
Tobramycin—Musculoskeletal discomfort—Niacin—atherosclerosis	0.00178	0.00178	CcSEcCtD
Tobramycin—Dizziness—Rosuvastatin—atherosclerosis	0.00177	0.00177	CcSEcCtD
Tobramycin—Urticaria—Ezetimibe—atherosclerosis	0.00177	0.00177	CcSEcCtD
Tobramycin—Abdominal pain—Ezetimibe—atherosclerosis	0.00176	0.00176	CcSEcCtD
Tobramycin—Body temperature increased—Ezetimibe—atherosclerosis	0.00176	0.00176	CcSEcCtD
Tobramycin—Paraesthesia—Niacin—atherosclerosis	0.00175	0.00175	CcSEcCtD
Tobramycin—Feeling abnormal—Simvastatin—atherosclerosis	0.00175	0.00175	CcSEcCtD
Tobramycin—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.00175	0.00175	CcSEcCtD
Tobramycin—Dyspnoea—Niacin—atherosclerosis	0.00174	0.00174	CcSEcCtD
Tobramycin—Gastrointestinal pain—Simvastatin—atherosclerosis	0.00174	0.00174	CcSEcCtD
Tobramycin—Paraesthesia—Pravastatin—atherosclerosis	0.00173	0.00173	CcSEcCtD
Tobramycin—Dyspnoea—Pravastatin—atherosclerosis	0.00171	0.00171	CcSEcCtD
Tobramycin—Decreased appetite—Niacin—atherosclerosis	0.0017	0.0017	CcSEcCtD
Tobramycin—Rash—Rosuvastatin—atherosclerosis	0.00169	0.00169	CcSEcCtD
Tobramycin—Dermatitis—Rosuvastatin—atherosclerosis	0.00169	0.00169	CcSEcCtD
Tobramycin—Urticaria—Simvastatin—atherosclerosis	0.00169	0.00169	CcSEcCtD
Tobramycin—Gastrointestinal disorder—Niacin—atherosclerosis	0.00169	0.00169	CcSEcCtD
Tobramycin—Abdominal pain—Simvastatin—atherosclerosis	0.00168	0.00168	CcSEcCtD
Tobramycin—Body temperature increased—Simvastatin—atherosclerosis	0.00168	0.00168	CcSEcCtD
Tobramycin—Headache—Rosuvastatin—atherosclerosis	0.00168	0.00168	CcSEcCtD
Tobramycin—Hypersensitivity—Lovastatin—atherosclerosis	0.00167	0.00167	CcSEcCtD
Tobramycin—Decreased appetite—Pravastatin—atherosclerosis	0.00167	0.00167	CcSEcCtD
Tobramycin—Pain—Niacin—atherosclerosis	0.00167	0.00167	CcSEcCtD
Tobramycin—Pain—Pravastatin—atherosclerosis	0.00164	0.00164	CcSEcCtD
Tobramycin—Hypersensitivity—Ezetimibe—atherosclerosis	0.00164	0.00164	CcSEcCtD
Tobramycin—Asthenia—Lovastatin—atherosclerosis	0.00163	0.00163	CcSEcCtD
Tobramycin—Pruritus—Lovastatin—atherosclerosis	0.00161	0.00161	CcSEcCtD
Tobramycin—Asthenia—Ezetimibe—atherosclerosis	0.0016	0.0016	CcSEcCtD
Tobramycin—Gastrointestinal pain—Niacin—atherosclerosis	0.0016	0.0016	CcSEcCtD
Tobramycin—Nausea—Rosuvastatin—atherosclerosis	0.00159	0.00159	CcSEcCtD
Tobramycin—Feeling abnormal—Pravastatin—atherosclerosis	0.00158	0.00158	CcSEcCtD
Tobramycin—Pruritus—Ezetimibe—atherosclerosis	0.00158	0.00158	CcSEcCtD
Tobramycin—Gastrointestinal pain—Pravastatin—atherosclerosis	0.00157	0.00157	CcSEcCtD
Tobramycin—Hypersensitivity—Simvastatin—atherosclerosis	0.00157	0.00157	CcSEcCtD
Tobramycin—Diarrhoea—Lovastatin—atherosclerosis	0.00155	0.00155	CcSEcCtD
Tobramycin—Urticaria—Niacin—atherosclerosis	0.00155	0.00155	CcSEcCtD
Tobramycin—Body temperature increased—Niacin—atherosclerosis	0.00154	0.00154	CcSEcCtD
Tobramycin—Abdominal pain—Niacin—atherosclerosis	0.00154	0.00154	CcSEcCtD
Tobramycin—Urticaria—Pravastatin—atherosclerosis	0.00153	0.00153	CcSEcCtD
Tobramycin—Asthenia—Simvastatin—atherosclerosis	0.00153	0.00153	CcSEcCtD
Tobramycin—Diarrhoea—Ezetimibe—atherosclerosis	0.00153	0.00153	CcSEcCtD
Tobramycin—Abdominal pain—Pravastatin—atherosclerosis	0.00152	0.00152	CcSEcCtD
Tobramycin—Body temperature increased—Pravastatin—atherosclerosis	0.00152	0.00152	CcSEcCtD
Tobramycin—Pruritus—Simvastatin—atherosclerosis	0.0015	0.0015	CcSEcCtD
Tobramycin—Dizziness—Lovastatin—atherosclerosis	0.0015	0.0015	CcSEcCtD
Tobramycin—Dizziness—Ezetimibe—atherosclerosis	0.00147	0.00147	CcSEcCtD
Tobramycin—Diarrhoea—Simvastatin—atherosclerosis	0.00145	0.00145	CcSEcCtD
Tobramycin—Vomiting—Lovastatin—atherosclerosis	0.00145	0.00145	CcSEcCtD
Tobramycin—Hypersensitivity—Niacin—atherosclerosis	0.00144	0.00144	CcSEcCtD
Tobramycin—Rash—Lovastatin—atherosclerosis	0.00143	0.00143	CcSEcCtD
Tobramycin—Dermatitis—Lovastatin—atherosclerosis	0.00143	0.00143	CcSEcCtD
Tobramycin—Headache—Lovastatin—atherosclerosis	0.00142	0.00142	CcSEcCtD
Tobramycin—Vomiting—Ezetimibe—atherosclerosis	0.00142	0.00142	CcSEcCtD
Tobramycin—Hypersensitivity—Pravastatin—atherosclerosis	0.00142	0.00142	CcSEcCtD
Tobramycin—Dizziness—Simvastatin—atherosclerosis	0.00141	0.00141	CcSEcCtD
Tobramycin—Rash—Ezetimibe—atherosclerosis	0.00141	0.00141	CcSEcCtD
Tobramycin—Dermatitis—Ezetimibe—atherosclerosis	0.0014	0.0014	CcSEcCtD
Tobramycin—Asthenia—Niacin—atherosclerosis	0.0014	0.0014	CcSEcCtD
Tobramycin—Headache—Ezetimibe—atherosclerosis	0.0014	0.0014	CcSEcCtD
Tobramycin—Pruritus—Niacin—atherosclerosis	0.00138	0.00138	CcSEcCtD
Tobramycin—Asthenia—Pravastatin—atherosclerosis	0.00138	0.00138	CcSEcCtD
Tobramycin—Pruritus—Pravastatin—atherosclerosis	0.00136	0.00136	CcSEcCtD
Tobramycin—Vomiting—Simvastatin—atherosclerosis	0.00135	0.00135	CcSEcCtD
Tobramycin—Nausea—Lovastatin—atherosclerosis	0.00135	0.00135	CcSEcCtD
Tobramycin—Rash—Simvastatin—atherosclerosis	0.00134	0.00134	CcSEcCtD
Tobramycin—Dermatitis—Simvastatin—atherosclerosis	0.00134	0.00134	CcSEcCtD
Tobramycin—Diarrhoea—Niacin—atherosclerosis	0.00134	0.00134	CcSEcCtD
Tobramycin—Headache—Simvastatin—atherosclerosis	0.00133	0.00133	CcSEcCtD
Tobramycin—Nausea—Ezetimibe—atherosclerosis	0.00132	0.00132	CcSEcCtD
Tobramycin—Diarrhoea—Pravastatin—atherosclerosis	0.00131	0.00131	CcSEcCtD
Tobramycin—Dizziness—Niacin—atherosclerosis	0.00129	0.00129	CcSEcCtD
Tobramycin—Dizziness—Pravastatin—atherosclerosis	0.00127	0.00127	CcSEcCtD
Tobramycin—Nausea—Simvastatin—atherosclerosis	0.00126	0.00126	CcSEcCtD
Tobramycin—Vomiting—Niacin—atherosclerosis	0.00124	0.00124	CcSEcCtD
Tobramycin—Rash—Niacin—atherosclerosis	0.00123	0.00123	CcSEcCtD
Tobramycin—Dermatitis—Niacin—atherosclerosis	0.00123	0.00123	CcSEcCtD
Tobramycin—Headache—Niacin—atherosclerosis	0.00122	0.00122	CcSEcCtD
Tobramycin—Vomiting—Pravastatin—atherosclerosis	0.00122	0.00122	CcSEcCtD
Tobramycin—Rash—Pravastatin—atherosclerosis	0.00121	0.00121	CcSEcCtD
Tobramycin—Dermatitis—Pravastatin—atherosclerosis	0.00121	0.00121	CcSEcCtD
Tobramycin—Headache—Pravastatin—atherosclerosis	0.0012	0.0012	CcSEcCtD
Tobramycin—Nausea—Niacin—atherosclerosis	0.00116	0.00116	CcSEcCtD
Tobramycin—Nausea—Pravastatin—atherosclerosis	0.00114	0.00114	CcSEcCtD
